natgillin/translations-raw huggingface dataset:
Undesirable effects where the frequency is not known are: - headache, - ringing in the ears, - cough, - taste disturbance, - indigestion, - pain in joints and muscles, - liver function abnormal and impaired kidney function, - increased level of potassium in your blood and - allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
Nuspojave čija učestalost nije poznata su: - glavobolja - zvonjenje u ušima - kašalj - poremećaj okusa - probavne tegobe - bol u zglobovima i mišićima - abnormalna funkcija jetre i oštećena funkcija bubrega - povišena razina kalija u krvi i - alergijske reakcije kao što su osip, urtikarija, oticanje lica, usana, usta, jezika ili grla - prijavljeni su i manje česti slučajevi žutice (žuta boja kože i/ili bjeloočnica).
Non-steroidal anti-inflammatory drugs:
Nesteroidni protuupalni lijekovi:
Lithium:
Litij:
Not known: aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
Nije poznato: aplastična anemija, depresija koštane srži, neutropenija/agranulocitoza, hemolitička anemija, leukopenija, trombocitopenija
Ifirmacombi 300 mg/25 mg film-coated tablets EU/1/11/673/017-024
Ifirmacombi 300 mg/25 mg filmom obložene tablete EU/1/11/673/017-024
The most likely manifestations of irbesartan overdose are expected to be hypotension and tachycardia; bradycardia might also occur.
Najčešće očekivane manifestacije predoziranja irbesartanom su hipotenzija i tahikardija.
Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Ifirmacombi.
Nadalje, tiazidi smanjuju renalni klirens litija pa uzimanje lijeka Ifirmacombi može povećati rizik od toksičnosti litija.
Iron oxide, yellow (E172)
titanijev dioksid (E171) makrogol talk željezov oksid, žuti (E172) željezov oksid, crveni (E172)
Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).
Poznato je da u ljudi terapija antagonistima receptora angiotenzina II tijekom drugog i trećeg tromjesečja izaziva fetotoksičnost (smanjena bubrežna funkcija, oligohidramnion, poremećaj okoštavanja lubanje) i neonatalnu toksičnost (zatajenje bubrega, hipotenzija, hiperkalijemija) (vidjeti dio 5.3).
In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of irbesartan gave an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mmHg.
Bolesnicima čiji se tlak ne može učinkovito kontrolirati samo s 25 mg hidroklorotiazida, dodatak irbesartana omogućuje dodatno srednje smanjenje sistoličkog/dijastoličkog tlaka (korigirano za placebo) od 11,1/7,2 mmHg.
The use of Ifirmacombi during breast feeding is not recommended.
Ne preporučuje se upotreba lijeka Ifirmacombi tijekom dojenja.
Blood and lymphatic system disorders:
Poremećaji krvi i limfnog sustava
Not known: depression, sleep disturbances Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed (see also sections 4.4 and
Nemelanomski rak kože: Na temelju dostupnih podataka iz epidemioloških ispitivanja, između hidroklorotiazida i NMSC-a primijećena je povezanost ovisna o kumulativnoj dozi (vidjeti također dijelove 4.4 i 5.1).
Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose.
U ispitivanjima na mužjacima i ženkama štakora, čak i peroralne doze irbesartana koje uzrokuju manju parentalnu toksičnost (od 50 do 650 mg/kg/dan), uključujući mortalitet pri najvišoj dozi, nisu utjecale na plodnost i reproduktivnu sposobnost.
If you take more Ifirmacombi than you should If you accidentally take too many tablets, contact your doctor immediately.
Ako slučajno uzmete previše tableta, odmah se obratite svom liječniku.
How to store Ifirmacombi
Kako čuvati Ifirmacombi
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mmHg.
Dodatak 12,5 mg hidroklorotiazida dozi od 300 mg irbesartana jedanput na dan bolesnicima koji nisu odgovarajuće kontrolirani s 300 mg irbesartana u monoterapiji doveo je do daljnjeg smanjenja dijastoličkog krvnog tlaka (u usporedbi s placebom) za 6,1 mm Hg u vrijeme najniže koncentracije u krvi (24 sata nakon uzimanja doze).
Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.
Ako intraokularni tlak ostane nekontroliran, možda će biti potrebno razmotriti hitno medicinsko ili kirurško liječenje.
Lithium: The combination of lithium and Ifirmacombi is not recommended (see section 4.5).
Litij: Ne preporučuje se kombinacija litija i lijeka Ifirmacombi (vidjeti dio 4.5).
Forty-seven percent (47.2%) of patients on the combination achieved trough SeDBP < 90 mmHg compared to 33.2% of patients on irbesartan (p = 0.0005).
Pri najnižoj koncentraciji lijeka u krvi, 47,2% bolesnika koji su primali kombinaciju irbesartan/hidroklorotiazid postiglo je dijastolički tlak < 90 mmHg, u usporedbi sa 33,2% bolesnika koji su primali irbesartan (p < 0,0005).
The combination of 300 mg irbesartan and 12.5 mg hydrochlorothiazide resulted in an overall placebo-subtracted systolic/diastolic reductions of up to 13.6/11.5 mmHg.
Kombinacija 300 mg irbesartana i 12,5 mg hidroklorotiazida dovela je do sveukupnog sniženja sistoličkog/dijastoličkog krvnog tlaka (korigiranim za rezultate placebo skupine) za 13,6/11,5 mm Hg.
When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebo-subtracted systolic/diastolic reductions of 15.8/10.0 mmHg.
Na osnovi ambulantnih mjerenja krvnog tlaka utvrđeno je da kombinacija od 150 mg irbesartana i 12,5 mg hidroklorotiazida jedanput na dan uzrokuje konzistentno smanjenje krvnog tlaka u periodu od 24 sata, sa srednjim 24satnim smanjenjem sistoličkog/dijastoličkog krvnog tlaka (korigiranim za rezultate placebo skupine) od 15,8/10,0 mm Hg.
No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is ≥ 30 ml/min.
Nije potrebno prilagođavati dozu u bolesnika koji imaju oslabljenu funkciju bubrega s klirensom kreatinina ≥ 30 ml/min.
nausea/vomiting diarrhoea dyspepsia, dysgeusia
mučnina/povraćanje proljev dispepsija, poremećaj okusa
Not known Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)
Nije poznato: nemelanomski rak kože (karcinom bazalnih stanica i karcinom skvamoznih stanica)
Medicinal products affected by serum potassium disturbances:
Lijekovi na koje utječu poremećaji razine kalija u serumu:
- If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Ifirmacombi” and “Warnings and precautions”)
“Nemojte uzimati Ifirmacombi” i “Upozorenja i mjere opreza”).
Ifirmacombi 300 mg/12.5 mg film-coated tablets EU/1/11/673/009-016
Ifirmacombi 300 mg/12,5 mg filmom obložene tablete EU/1/11/673/009-016
Electrolyte imbalance:
Poremećaj elektrolita:
No dosage adjustment is necessary in female patients.
Nije potrebna prilagodba doziranja u bolesnica.
Ifirmacombi 150 mg/12.5 mg film-coated tablets EU/1/11/673/001-008
Ifirmacombi 150 mg/12,5 mg filmom obložene tablete EU/1/11/673/001-008
Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy.
Tijekom trudnoće ne smiju se uvoditi antagonisti receptora angiotenzina II.
Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses in patients without risk of electrolyte imbalance (see sections 4.4 and 4.5).
Pri preporučenim dozama, u bolesnika bez rizika od poremećaja ravnoteže elektrolita, irbesartan u monoterapiji ne utječe značajno na razinu serumskog kalija (vidjeti dijelove 4.4 i 4.5).
EU/1/11/673/017 (14 film-coated tablets) EU/1/11/673/018 (28 film-coated tablets) EU/1/11/673/019 (30 film-coated tablets) EU/1/11/673/020 (56 film-coated tablets) EU/1/11/673/021 (56 x 1 film-coated tablets) EU/1/11/673/022 (84 film-coated tablets) EU/1/11/673/023 (90 film-coated tablets) EU/1/11/673/024 (98 film-coated tablets)
EU/1/11/673/017 (14 filmom obloženih tableta) EU/1/11/673/018 (28 filmom obloženih tableta) EU/1/11/673/019 (30 filmom obloženih tableta) EU/1/11/673/020 (56 filmom obloženih tableta) EU/1/11/673/021 (56 x 1 filmom obloženih tableta) EU/1/11/673/022 (84 filmom obložene tablete) EU/1/11/673/023 (90 filmom obloženih tableta) EU/1/11/673/024 (98 filmom obloženih tableta)
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) - Second and third trimesters of pregnancy (see sections 4.4 and 4.6) - Severe renal impairment (creatinine clearance < 30 ml/min) - Refractory hypokalaemia, hypercalcaemia - Severe hepatic impairment, biliary cirrhosis and cholestasis - The concomitant use of Ifirmacombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1 ili na druge tvari koje su derivati sulfonamida (hidroklorotiazid je derivat sulfonamida) Drugo i treće tromjesečje trudnoće (vidjeti dijelove 4.4 i 4.6) Teško oštećenje funkcije bubrega (klirens kreatinina < 30 ml/min) Refraktorna hipokalijemija, hiperkalcijemija
The recommended dose of Ifirmacombi 150 mg/12.5 mg is one tablet a day.
Preporučena doza lijeka Ifirmacombi 150 mg/12,5 mg je jedna tableta na dan.
EU/1/11/673/001 (14 film-coated tablets) EU/1/11/673/002 (28 film-coated tablets) EU/1/11/673/003 (30 film-coated tablets) EU/1/11/673/004 (56 film-coated tablets) EU/1/11/673/005 (56 x 1 film-coated tablets) EU/1/11/673/006 (84 film-coated tablets) EU/1/11/673/007 (90 film-coated tablets) EU/1/11/673/008 (98 film-coated tablets)
EU/1/11/673/001 (14 filmom obloženih tableta) EU/1/11/673/002 (28 filmom obloženih tableta) EU/1/11/673/003 (30 filmom obloženih tableta) EU/1/11/673/004 (56 filmom obloženih tableta) EU/1/11/673/005 (56 x 1 filmom obloženih tableta) EU/1/11/673/006 (84 filmom obložene tablete) EU/1/11/673/007 (90 filmom obloženih tableta) EU/1/11/673/008 (98 filmom obloženih tableta)
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics.
Pretpostavka je da istodobna primjena irbesartana te posljedična blokada sustava renin-angiotenzin-aldosteron utječe na sprječavanje gubitka kalija povezanog s primjenom tih diuretika.
The recommended dose of Ifirmacombi 300 mg/25 mg is one tablet a day.
Preporučena doza lijeka Ifirmacombi 300 mg/25 mg je jedna tableta na dan.
EU/1/11/673/009 (14 film-coated tablets) EU/1/11/673/010 (28 film-coated tablets) EU/1/11/673/011 (30 film-coated tablets) EU/1/11/673/012 (56 film-coated tablets) EU/1/11/673/013 (56 x 1 film-coated tablets) EU/1/11/673/014 (84 film-coated tablets) EU/1/11/673/015 (90 film-coated tablets) EU/1/11/673/016 (98 film-coated tablets)
EU/1/11/673/009 (14 filmom obloženih tableta) EU/1/11/673/010 (28 filmom obloženih tableta) EU/1/11/673/011 (30 filmom obloženih tableta) EU/1/11/673/012 (56 filmom obloženih tableta) EU/1/11/673/013 (56 x 1 filmom obloženih tableta) EU/1/11/673/014 (84 filmom obložene tablete) EU/1/11/673/015 (90 filmom obloženih tableta) EU/1/11/673/016 (98 filmom obloženih tableta)
Not known: vertigo, paraesthesia, light-headedness, restlessness
Nije poznato: vrtoglavica, parestezija, ošamućenost, nemir
Irbesartan/hydrochlorothiazide
Irbesartan/hidroklorotiazid:
Not known: cardiac arrhythmias
Nije poznato: srčane aritmije
Warnings and precautions Talk to your doctor before taking Ifirmacombi and if any of the following apply to you: - if you get excessive vomiting or diarrhoea - if you suffer from kidney problems or have a kidney transplant - if you suffer from heart problems - if you suffer from liver problems - if you suffer from diabetes - if you suffer from lupus erythematosus (also known as lupus or SLE) - if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
- ako značajno povraćate ili imate jaki proljev - ako imate problema s bubrezima ili ste imali transplantaciju bubrega - ako imate srčanih problema - ako imate problema s jetrom - ako bolujete od šećerne bolesti - ako bolujete od eritemskog lupusa (poznat i kao lupus ili SLE) - ako bolujete od primarnog aldosteronizma (stanje povezano s visokom proizvodnjom hormona aldosterona koji uzrokuje zadržavanje natrija u tijelu i, posljedično, povećanje krvnog tlaka) - ako ste imali rak kože ili ako Vam se pojavi neočekivana lezija (promjena) na koži tijekom liječenja.
When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.
Kada se utvrdi trudnoća, mora se odmah prekinuti liječenje antagonistima receptora angiotenzina II te treba, ako je to primjereno, uvesti drugu odgovarajuću terapiju.
Medicinal products affecting potassium:
Lijekovi koji utječu na razinu kalija:
The recomended dose of Ifirmacombi 300 mg /12.5 mg is one tablet a day.
Preporučena doza lijeka Ifirmacombi 300 mg/12,5 mg je jedna tableta na dan.
Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism for this is unknown.
Farmakokinetika irbesartana je linearna i proporcionalna dozi u rasponu doza od 10 do 600 mg.
Hydrochlorothiazide
Hidroklorotiazid:
Psychiatric disorders:
Psihijatrijski poremećaji
Ifirmacombi 150 mg/12.5 mg film-coated tablets Pale pink, biconvex, oval, film-coated tablets.
Ifirmacombi 150 mg/12,5 mg filmom obložene tablete Blijedo ružičaste, bikonveksne, ovalne, filmom obložene tablete.
Ifirmacombi 150 mg/12.5 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172) and red iron oxide (E172) in the film-coating.
Ifirmacombi 150 mg/12,5 mg: manitol, hidroksipropilceluloza, nisko supstituirana hidroksipropilceluloza, natrijev škroboglikolat, talk, makrogol 6000, hidrogenirano ricinusovo ulje u jezgri tablete i poli(vinilni alkohol), titanijev dioksid (E171), makrogol, talk, žuti željezov oksid (E172) i crveni željezov oksid (E172) u film ovojnici tablete.
Ifirmacombi 300 mg/25 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172) and red iron oxide (E172) in the film-coating.
Ifirmacombi 300 mg/25 mg: manitol, hidroksipropilceluloza, nisko supstituirana hidroksipropilceluloza, natrijev škroboglikolat, talk, makrogol 6000, hidrogenirano ricinusovo ulje u jezgri tablete i poli(vinilni alkohol), titanijev dioksid (E171), makrogol, talk, žuti željezov oksid (E172) i crveni željezov oksid (E172) u film ovojnici tablete.
Ifirmacombi 150 mg/12.5 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Liječnik će Vam obično propisati Ifirmacombi 150 mg/12,5 mg ako Vam dosadašnje liječenje povišenog krvnog tlaka nije osiguralo odgovarajući učinak.
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets
Ifirmacombi 150 mg/12,5 mg filmom obložene tablete Ifirmacombi 300 mg/12,5 mg filmom obložene tablete Ifirmacombi 300 mg/25 mg filmom obložene tablete
Uncommon: chest pain
Manje često: bol u prsima
Ifirmacombi 300 mg/12.5 mg: mannitol, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, sodium starch glycolate, talc, macrogol 6000, hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), macrogol, talc in the film-coating.
Ifirmacombi 300 mg/12,5 mg: manitol, hidroksipropilceluloza, nisko supstituirana hidroksipropilceluloza, natrijev škroboglikolat, talk, makrogol 6000, hidrogenirano ricinusovo ulje u jezgri tablete i poli(vinilni alkohol), titanijev dioksid (E171), makrogol, talk u film ovojnici tablete.
- if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems - Aliskiren
Zaštitite svoju kožu od izlaganja suncu i UV zrakama za vrijeme uzimanja lijeka Ifirmacombi. - ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: - ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću. - aliskiren.
Common side effects (may affect up to 1 in 10 people): - nausea/vomiting - abnormal urination - fatigue - dizziness (including when getting up from a lying or sitting position) - blood tests may show raised levels of an enzyme that measures the muscle and heart function
- omaglica (uključujući onu koja se javlja nakon dizanja iz ležećeg ili sjedećeg položaja) - krvnim pretragama dokazane povišene vrijednosti enzima koji određuje funkciju srca i mišića
Hydroxypropylcellulose Hydroxypropylcellulose, low-substituted Sodium starch glycolate Talc
Jezgra tablete: manitol hidroksipropilceluloza hidroksipropilceluloza, nisko supstituirana natrijev škroboglikolat talk makrogol 6000 ricinusovo ulje, hidrogenirano
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets Irbesartan/Hydrochlorothiazide
Ifirmacombi 150 mg/12,5 mg filmom obložene tablete Ifirmacombi 300 mg/12,5 mg filmom obložene tablete Ifirmacombi 300 mg/25 mg filmom obložene tablete irbesartan/hidroklorotiazid
Ifirmacombi 300 mg/25 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Liječnik će Vam obično propisati Ifirmacombi 300 mg/25 mg ako Vam dosadašnje liječenje povišenog krvnog tlaka nije osiguralo odgovarajući učinak.
- Ifirmacombi 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; - Ifirmacombi 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Ifirmacombi 150 mg/12.5 mg. - Ifirmacombi 300 mg/25 mg may be administered in patients insufficiently controlled by Ifirmacombi 300 mg/12.5 mg.
Ifirmacombi 300 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati irbesartanom u dozi od 300 mg ili lijekom Ifirmacombi 150 mg/12,5 mg.
Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg in patients with mild-to-moderate hypertension.
U bolesnika s blagom do srednje teškom hipertenzijom doza od 150 mg irbesartana i 12,5 mg hidroklorotiazida jedanput na dan dovela je do srednjeg sniženja sistoličkog/dijastoličkog krvnog tlaka od 12,9/6,9 mm Hg (korigirano za rezultate placebo skupine) u vrijeme najniže koncentracije u krvi (24 sata nakon uzimanja doze).
However, another angiotensin-II antagonist affected fertility parameters in animal studies when given alone.
Rezultati ispitivanja na životinjskim modelima pokazali su, međutim, da je jedan drugi antagonist receptora angiotenzina II primijenjen sam utjecao na parametre fertilnosti.
Ifirmacombi 300 mg/12.5 mg will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Liječnik će Vam obično propisati Ifirmacombi 300 mg/12,5 mg ako Vam dosadašnje liječenje povišenog krvnog tlaka nije osiguralo odgovarajući učinak.
A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force titrated (before assessing the response to the lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively.
Nakon jednog tjedna doze su sustavno forsirano titrirane (prije procjene odgovora na nisku dozu) na irbesartan/hidroklorotiazid 300 mg/25 mg, odnosno irbesartan 300 mg.
No dosage adjustment of Ifirmacombi is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Za bolesnike s blago ili umjereno oštećenom funkcijom jetre nije potrebna prilagodba doze lijeka Ifirmacombi (vidjeti dio 4.3).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution.
Međutim, kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenom funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali < 60 ml/min).
Tablet core:
Oštećena funkcija bubrega:
Ifirmacombi 300 mg/12.5 mg White, biconvex, capsule shaped, film-coated tablets (tablets).
Ifirmacombi 300 mg/12,5 mg Bijele, bikonveksne, filmom obložene tablete u obliku kapsule (tablete).
Periodic monitoring of serum potassium is recommended when Ifirmacombi is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).
Pri istodobnoj primjeni lijeka Ifirmacombi i drugih lijekova na čije djelovanje utječu poremećaji kalija (primjerice glikozidi digitalisa, antiaritmici) preporučuje se periodičko praćenje razine kalija u serumu.
Ifirmacombi 300 mg/25 mg film-coated tablets Pale pink, biconvex, capsule shaped, film-coated tablets.
Ifirmacombi 300 mg/25 mg filmom obložene tablete Blijedo ružičaste, bikonveksne, filmom obložene tablete u obliku kapsule.
(It is also better to avoid Ifirmacombi in early pregnancy - see pregnancy section) - if you have severe liver or kidney problems - if you have difficulty in producing urine - if your doctor determines that you have persistently high calcium or low potassium levels in your blood - if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren
Nemojte uzimati Ifirmacombi - ako ste alergični na irbesartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) - ako ste alergični na hidroklorotiazid ili lijekove kemijski srodne sulfonamidima - ako ste trudni više od 3 mjeseca (preporučuje se, također, izbjegavati Ifirmacombi i u ranoj trudnoći - vidjeti dio o trudnoći) - ako imate teških problema s jetrom ili bubrezima - ako imate poteškoća sa stvaranjem urina - ako Vaš liječnik utvrdi da imate poremećaj koji je povezan sa stalno povišenom razinom kalcija ili niskom razinom kalija u krvi - ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren
Ifirmacombi 300 mg/12.5 mg film-coated tablets White, biconvex, capsule shaped, film-coated tablets.
Ifirmacombi 300 mg/12,5 mg filmom obložene tablete Bijele, bikonveksne, filmom obložene tablete u obliku kapsule.
Ifirmacombi 300 mg/25 mg tablets Irbesartan/Hydrochlorothiazide
Ifirmacombi 300 mg/25 mg tablete irbesartan/hidroklorotiazid
Ifirmacombi 300 mg/25 mg Pale pink, biconvex, capsule shaped, film-coated tablets (tablets).
Ifirmacombi 300 mg/25 mg Blijedo ružičaste, bikonveksne, filmom obložene tablete u obliku kapsule (tablete).